Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 1.22B | 1.25B | 1.34B | 932.64M | 534.82M | 499.63M |
Gross Profit | 579.51M | 772.59M | 112.62M | 588.60M | 322.54M | 303.12M |
EBITDA | 607.44M | 711.56M | 780.51M | 555.62M | 287.60M | 274.18M |
Net Income | -391.06M | -654.49M | -278.26M | -106.00M | 14.32M | 19.19M |
Balance Sheet | ||||||
Total Assets | 10.50B | 10.65B | 12.64B | 13.85B | 4.26B | 3.81B |
Cash, Cash Equivalents and Short-Term Investments | 25.72M | 68.92M | 25.70M | 60.96M | 13.18M | 15.30M |
Total Debt | 5.03B | 4.96B | 5.30B | 5.70B | 1.92B | 1.71B |
Total Liabilities | 5.35B | 5.35B | 5.71B | 6.17B | 2.07B | 1.86B |
Stockholders Equity | 5.08B | 5.23B | 6.82B | 7.57B | 2.19B | 1.95B |
Cash Flow | ||||||
Free Cash Flow | 205.53M | 252.64M | 268.79M | 109.20M | 131.94M | 376.13M |
Operating Cash Flow | 473.25M | 501.62M | 499.82M | 272.75M | 232.63M | 470.09M |
Investing Cash Flow | 920.65M | 900.92M | 349.14M | 1.63B | -562.47M | -555.17M |
Financing Cash Flow | -1.39B | -1.36B | -884.22M | -1.86B | 327.72M | 99.72M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
78 Outperform | $5.98B | 34.00 | 7.02% | 4.29% | 43.27% | 80.97% | |
77 Outperform | $4.43B | 31.51 | 5.15% | 6.45% | 7.81% | 179.16% | |
76 Outperform | $3.31B | 22.47 | 10.56% | 5.08% | 7.44% | 4.23% | |
68 Neutral | $5.99B | ― | -1.93% | 2.70% | 11.30% | ― | |
65 Neutral | £989.01M | 11.77 | -0.08% | 5.05% | 10.32% | 31.28% | |
59 Neutral | $5.59B | ― | -6.83% | 7.79% | -7.26% | 18.45% | |
52 Neutral | $2.63B | ― | -28.86% | 7.31% | 19.56% | -12.73% |
On June 18, 2025, Healthcare Realty Trust announced the voluntary retirement of five directors from its Board, reducing its size from 12 to 7 members. This strategic move aligns the Board’s size with industry standards and reinforces the company’s commitment to best practices in corporate governance. The changes are expected to enhance shareholder engagement and drive value, with the remaining directors focused on strengthening stakeholder relationships and capitalizing on strong industry fundamentals.
The most recent analyst rating on (HR) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Healthcare Realty Trust stock, see the HR Stock Forecast page.
On May 20, 2025, Healthcare Realty Trust‘s Board of Directors appointed Peter A. Scott as a director and increased the board size to 12 members, with plans to reduce it in the future. Mr. Scott, who became the company’s President and CEO on April 15, 2025, will serve on the Capital Allocation Committee. At the annual stockholders’ meeting on May 20, 2025, several directors were elected, and key proposals, including the ratification of BDO USA, P.C. as the independent accounting firm and executive compensation, were approved.
The most recent analyst rating on (HR) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Healthcare Realty Trust stock, see the HR Stock Forecast page.
Healthcare Realty Trust reported a net loss of $44.9 million for the first quarter of 2025, with a normalized FFO per share of $0.39. The company declared a quarterly dividend of $0.31 per share and announced leadership changes with Peter A. Scott appointed as President & CEO. The company also highlighted a slight increase in same-store occupancy and tenant retention, alongside significant leasing activity and asset sale transactions.
Healthcare Realty Trust has appointed Peter A. Scott as its new President and CEO, effective April 15, 2025, following a rigorous search process. Scott, who previously served as CFO of Healthpeak Properties, brings extensive experience in healthcare real estate and investment banking. His appointment is expected to bolster the company’s growth and operational strategies, leveraging his expertise in strategic mergers and financial restructuring. Concurrently, Constance B. Moore will step down as Interim President and CEO but will remain on the Board, ensuring a smooth transition.